Revenue announcement ( ie. Lympro) will knock pps out of the ball park...("the Company intends to be first to market with a biologically relevant diagnostic blood test for Alzheimer's." ). There just isn't any buying pressure here today, so far...
No one should be consumed with daily fluctuations in share price.

http://online.wsj.com/article/PR-CO-20140505-904731.html